Program
KINE-101
A development code.
Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Kine Sciences.
Furthest: phase 1, since Dec 9, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kine Sciences | 30 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2025First studies: 3 phase 1 studiesFirst studyNCT07324642, NCT07343323, NCT07343310
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07343323Healthy Volunteers · United States | 1 | Completed | Jan 31, 2023 | 40 |
| NCT07343310Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · South Korea | 1 | Completed | Apr 14, 2025 | 9 |
| NCT07324642Healthy Volunteers · South Korea | 1 | Completed | Aug 25, 2025 | 24 |
How it is read
Names in the registry
- “KINE-101”, 3 entries
Codes read as this program: KINE101.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.